Purpose: To evaluate the efficacy of the combination of vinorelbine and gemcitabine as a non-platinum chemotherapy regimen in patients with inoperable locally-advanced or metastatic non-small-cell lung cancer (NSCLC). Efficacy was assessed primarily in terms of response rate, and secondarily in terms of toxicity, time to progression and survival.
phase II trial. Thirty-three patients were enrolled in the phase II trial, and 28 were evaluable for response. The overall intentto-treat response rate of all 45 patients was 40% (18 of 45), comprising 4 CR (9%) and 14 PR (31%). For the 28 evaluable patients who received the fortnightly chemotherapy the response rate was 46% (13 of 28), CR 11% (3 of 28) and PR 36% (10 of 28). Seven patients (25%) had stable disease. The oneyear cumulative survival rate for the 33 patients receiving the fortnightly chemotherapy was 24% and median time-toprogression 4 months (range 1-16 months). Median survival for these patients was eight months. Nine out of twelve patients in the pilot study (75%) suffered grade 3-4 neutropenia. There was one toxic death, attributed to neutropenic fever and sepsis, and two cases of pulmonary embolism. One patient suffered Grade 4 thrombocytopenia. Only eight patients (24%) on the fortnightly schedule suffered grade 3-4 neutropenia, resulting in dose reductions or delays for three of them (9%). None of the patients on the fortnightly schedule suffered thrombocytopenia or anaemia.
Introduction
Non-small-cell lung cancer (NSCLC) accounts for 75%-80% of lung cancer cases. The curative treatment of choice is complete surgical resection whenever possible. However, in most cases NSCLC is a systemic, unresectable disease and the search for effective systemic therapy is, therefore, of utmost importance if overall treatment results are to be improved.
Until recently only a few agents, namely , cisplatin, vindesine, mitomycin and ifosfamide, have demonstrated activity in more than 15% of patients. For many years, platinum-based combination regimens were the standard chemotherapy. A number of newer agents, including vinorelbine (VNR), a semi-synthetic vinca-alkaloid, and gemcitabine (GEM), an analogue of deoxycytidine with properties similar to those of cytarabine, are now available and showing activity as single agents in more than 20% of patients [1] [2] [3] [4] [5] . The clinical side-effects of these agents are mild with minimal alopecia and manageable nausea [6, 7] . Furthermore, some recent reports have proved that single-agent VNR or GEM improves the survival of NSCLC patients while providing good relief from symptoms [7] [8] [9] .
Relatively high response rates and better survival have been achieved by combining VNR with cisplatin. Depierre et al. randomly assigned 231 patients with NSCLC to monotherapy with VNR (30 mg/m 2 /week) or to weekly VNR combined with cisplatin once every three weeks. The response rates in the monotherapy and combined therapy arms were 16% and 43%, respectively. The median time to progression also favoured the combination therapy [10] . A larger study of 612 patients compared VNR alone (30 mg/m 2 ) with combinations of VNR and vindesine or cisplatin. This study found a significantly higher response rate among patients receiving VNR and cisplatin (30%), than among those receiving VNR alone (14%). Moreover, the patients treated by the combination regimen survived longer (40 weeks versus 31.5 weeks) [11] . One problem with the platinum-based combination regimens is a tendency for a lower doseintensity of VNR to be used because of toxic effects of treatment. Westeel et al. made an attempt to reduce leukopenia by alternating high and low doses of VNR within a cisplatin-VNR regimen (35 mg/m 2 in weeks 1, 3 and 5, and 17.5 mg/m 2 in weeks 2 and 4). However, this strategy did not improve VNR dose intensity [12] . Combining carboplatin instead of cisplatin with VNR has been reported to achieve the same level of response and survival, but with lower toxicity [13] .
Weekly GEM (1000 mg/m 2 ), combined with cisplatin (100 mg/m 2 ) every four weeks, has achieved response rates as high as 52%, and improved survival as compared to cisplatin alone [14] , or in combination with etoposide, where a one-year survival rate of 61% was achieved in 50 patients with stage III-IV NSCLC treated by this regimen [15] . However, grade 3-4 neutropenia was detected in 58% of the patients and 62% suffered grade 3-4 nausea and vomiting related to cisplatin administration. Similar toxicities have been reported in other studies. In a dose escalation study, 31 patients with NSCLC were given a fixed dose of cisplatin (50 mg/m 2 ) every three weeks plus escalating doses of VNR and GEM [16] . Two dose levels were reported to be fairly well tolerated (GEM 1200 mg/m 2 plus VNR 20 mg/m 2 ; and GEM 1000 mg/m 2 plus VNR 25 mg/m 2 , administered on days 1 and 8 of each cycle). Grade 4 neutropenia lasting longer than seven days was, however, experienced by 26% of the patients. The response rate was 52%, and the projected one-year survival 51%.
The encouraging response rates that have been obtained using regimens that incorporate either VNR or GEM or both for NSCLC, and the toxicity of regimes containing cisplatin, persuaded us to carry out a pilot study followed by a phase II study of VNR and GEM without cisplatin. We speculated that this regime might be both well tolerated and effective in terms of response rate and survival. To our knowledge, there are little mature data available on the efficacy and tolerance of GEM-VNR combinations in NSCLC.
Patients and methods
Patients with cytologically-or histologically-confirmed and measurable stage I1IB or IV NSCLC were eligible for the studies. Patients were required to be 18 years of age or older, to have ECOG performance Patients who achieved an objective response (PR or CR) after six cycles were allowed to continue with the treatment until relapse. Haematological toxicity (neutropenia) necessitated reductions or delays in the administration of VNR and/or GEM in the pilot study, so that the schedule was modified to a fortnightly regimen for the phase II study. The drugs were administered as an intravenous infusion, in 0.9% saline. VNR was administered as a rapid side infusion over 5-10 minutes, followed by a 30-minute infusion of GEM.
The doses of VNR and GEM were reduced by 50% if grade 2 (WHO criteria) haematological toxicity was present on the next treatment day; and were delayed by one week if grade 3-4 haematological toxicity was present on the next treatment day. If haematological recovery was not achieved within two weeks, the patient discontinued treatment. The doses of VNR and GEM were reduced by 50% if grade 2 liver toxicity occurred, and by 75% in instances of grade 3 toxicity. Treatment was delayed in instances of grade 4 liver toxicity, and discontinued if the liver toxicity was not resolved within three weeks
Statistical analysis
Cumulative survival was estimated using the product limit method. Frequency tables were analysed using the Fishers exact test. Survival between the groups was analysed using the log-rank test.
Results
Between September 1996 and March 1997, 12 patients were enrolled in the pilot study. Thirty-three patients were enrolled in the phase II study between March 1997 and February 1998. Patient characteristics are given in Response rates to chemotherapy are given in Table 2 . The overall intent-to-treat response rate of all 45 patients was 40% (18 of 45) comprising 4 CR (9%) and 14 PR (31%). For the seven patients treated only with the high-dose weekly schedule, the overall response rate in four evaluable patients was 75%, comprising one CR and two PRs. One patient had stable disease. Five of the patients enrolled in the pilot study received only one cycle of the weekly chemotherapy before changing to the fortnightly regimen. For the 28 evaluable patients who received only the fortnightly chemotherapy the response rate was 46% (13 of 28), CR 11% (3 of 28) and PR 36% (10 of 28). Seven patients (25%) had stable disease, lasting in three patients for longer than 4 months (range 5-15 months).
Survival
The median survival in the entire series (n = 45) was seven months (95% Brookmayer-Crowley confidence interval: 6-9 months). Twenty-seven percent of the patients were alive twelve months after starting chemotherapy (Figure la) . Median survival of the 33 patients treated with the fortnightly schedule was 8 months (95% CI: 5-9 months), one-year survival rate 24%, and median time to progression 4 months (range 1-16 months). There was no difference in survival between the patients treated by the weekly VNR-GEM schedule and those treated on the fortnightly schedule (P -0.82, Figure lb) .
Toxicity
All 45 patients were evaluable for toxicity, which was assessed in a total of 145 cycles; 20 cycles in the pilot study and 125 cycles in the phase II study. Haematological toxicity is summarised in Table 3 . The median number of 28-day cycles per patient in the phase II study was three, ranging from zero to eight cycles.
Nine of twelve patients (75%) suffered grade 3-4 neutropenia in the pilot study. There was one toxic death, attributed to neutropenic fever and sepsis, and two cases of pulmonary embolism. One patient suffered grade 4 thrombocytopenia.
The change in schedule resulted in a marked reduction in the rate of neutropenia. Only eight patients (24%) on the fortnightly schedule suffered grade 3-4 neutropenia (P = 0.0041 Fisher's exact test), resulting in dose reductions or delays for three of them (9%). Grade 3-4 neutropenic fever occurred in one patient (3%) and asthenia in three patients (9%). No patient on the fortnightly schedule suffered thrombocytopenia or anaemia. Otherwise, there were no significant non-haematological toxic events, and none of the patients suffered grade 2 alopecia or vomiting. 
Discussion
A meta-analysis of 52 randomised trials, which compared cisplatin-based combination chemotherapy to best supportive care, showed that cisplatin-containing chemotherapy slightly increases survival in patients with inoperable NSCLC [17] . Many studies have demonstrated that chemotherapy relieves pain and dyspnoea, and recent randomised studies have shown that combination chemotherapy can improve both the quality of life and survival [15, 18, 19] . There is enormous pressure to develop optimal chemotherapy which is efficacious, cost-effective, well tolerated and convenient. Since the establishment of platinum-based chemotherapy as standard treatment for advanced NSCLC, cisplatin has been extensively used. Cisplatin is, however, a toxic drug that may affect the patients' quality of life adversely, causing vomiting, neurotoxicity and nephrotoxicity. The next logical step for improving treatment would be to develop drug combinations in which cisplatin is replaced by new drugs which have been shown in randomised studies to have a beneficial effect on survival. The studies reported here were designed to test such an option. Vinorelbine and gemcitabine were chosen because, of the widely used new drugs, their characteristics are best documented, and they are also the most cost-effective.
The dosages selected for the pilot study were based on single-agent phase II trials, but they resulted in a very high rate (75%) of grade 3-4 neutropenia and one toxic death. This problem might have been solved, at least partially, by the use of growth factors. However, instead of combining granulocyte growth factors with the weekly regimen, we changed the weekly schedule to a fortnightly one, thereby sacrificing some dose intensity. In spite of this, 46% of the evaluable patients receiving the fortnightly chemotherapy responded, and median survival for all enrolled patients (n = 45) was seven months, and one-year survival 27%. This is similar to a one-year survival rate of 25% found in a metaanalysis of 51 trials [7] . Trials of VNR and cisplatin, and of GEM and cisplatin, have shown that both of these combinations are superior to cisplatin alone [11, 15, 20] .
Very little data is available concerning the combination of GEM and VNR in patients with NSCLC, and we are only aware of preliminary results published in abstract form. In a Spanish dose escalation study, doses of GEM up to 1250 mg/m 2 and of VNR at 30 mg/m 2 were used. Both drugs were given on days 1 and 8 of a threeweek schedule, and 13 (43%) of 30 treated patients achieved objective responses [21] . In this study, grade 4 toxicity was observed in three of eight patients receiving GEM at a dose of 1500 mg/m 2 . An Italian group used a similar schedule with a GEM dose of 1200 mg/m 2 and a VNR dose of 30 mg/m 2 . They achieved three CRs (5%) and 16 PRs (31%) in 52 patients with stage IIIB-IV NSCLC [22] . Grade 3-4 leukopenia and neurotoxicity were observed in 37% and 19%, respectively, of the patients. Nausea, alopecia and neurotoxicity were negligible in this study, and the overall median survival of the patients was nine months. These data are well in line with our results reported here, using fortnightly GEM and VNR.
Despite the heterogeneity of our patient population, in which 32 (71%) had stage IV disease and 8 (18%) had a WHO performance status of 2, the results are encouraging. Median survival for the eight patients with poor performance status was as long as 7.5 months. Four of them responded to the treatment.
Three patients in the pilot study were non-evaluable. Two of them died of pulmonary embolisms, and the third of toxic neutropenia which was clearly treatment-related. Four patients were non-evaluable in the phase II study, because they died of disease progression before completing two cycles of treatment.
Conclusions
The results presented here indicate that a two-weekly combination of gemcitabine (1250 mg/m 2 ) and vinorelbine (35 mg/m 2 ) yields the very satisfactory response rate of 46% when given as first-line chemotherapy to patients with stages I lib or IV NSCLC. The combination is well tolerated, with neutropenia as the main toxicity. Both gemcitabine and vinorelbine are easy to administer on an out-patient basis, and the combination is a cost-effective regimen [23, 24] . We suggest that this combination be tested in terms of efficacy, quality of life and cost-effectiveness in one of the new non-platinum triplet phase II studies [25, 26] , using a taxane as the third drug, or against a platinum-containing regime in a phase III study.
